Pliant Therapeutics Inc expected to post a loss of 85 cents a share - Earnings Preview

Pliant Therapeutics

05/08/2024 12:30

* Pliant Therapeutics Inc  PLRX.OQ   PLRX.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 7
(estimated) for the period ending June 30 2024
    * The South San Francisco California-based  company is
expected to
report a 96.9% increase in revenue to $488.33 thousand from $248
thousand a year ago, according to the mean estimate from 9
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Pliant Therapeutics Inc
is for
a loss of 85 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Pliant
Therapeutics Inc is $43.00​, above​ its last closing price
of $13.87. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.75       -0.77      -0.78     Missed  -1.1
 Dec. 31 2024  -0.77       -0.81      -0.69     Beat    15.2
 Jan. 1 0001   -0.76       -0.77      -0.70     Beat    9.7​
 Jun. 30 2023  -0.72       -0.71      -0.70     Beat    1.9
 ​​Jan.        -0.65       -0.67      -0.67     Met     -0.2
 1 0001                                                 
 Dec. 31 2022  -0.70       -0.70      -0.72     Missed  -2.8​
 Sep. 30 2022  -0.74       -0.74      -0.65     Beat    12.3
 Jan. 1 0001   -0.82       -0.81      -0.82     Missed  -1
 This summary was machine generated August 5 at 11:30 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)